MyMD Pharmaceuticals Inc (MYMD)

[leifsmith]

S1 portion of the SARS-CoV-2 Spike protein & NF-kB

"The S1 subunit of the SARS-CoV-2 spike protein activates NF-kB, a protein that controls not only the transcription of DNA but also cellular survival and cytokine production"

Published by Mercola, today, at https://articles.mercola.com/sites/articles/archive/2021/07/12/moderna-vaccine-experiment.aspx —this may have a paywall, so here is Mercola's summary of the article:

STORY AT-A-GLANCE
• In an audio recording, a Moderna representative admits that everyone who gets a COVID injection is a participant in the trial. He also admits long-term protective efficacy against COVID-19 is unknown

• Animal research shows the SARS-CoV-2 spike protein subunit directly damages the heart and causes myocarditis by triggering an exaggerated immune response — a cytokine storm — in the heart cells

• The S1 subunit of the SARS-CoV-2 spike protein activates NF-kB, a protein that controls not only the transcription of DNA but also cellular survival and cytokine production

• This disease process does not involve the ACE2 receptor but rather the toll-like receptor 4 (TLR4), which is responsible for the detection of pathogens and the initiation of innate immune responses

• A new and strange pattern is emerging: Many who suffer serious side effects from the COVID shots have normal lab workups, which makes diagnosing and treatment difficult

And what does MyMD-1 do? and what did its predecessor molecule, anatabine-citrate, do? Both molecules moderate activity of NF-kB.

Overactive NF-kB appears as a damaging agent in almost every disease process.

Now we see a possible therapeutic connection between MYMD-1 and NF-kB in moderating adverse reactions to the mRNA vaccines, specifically the harm being done by the unexpected escape and wide dispersion of spike protein as the vaccines force its production.

Isn't this support for what knuts4oe just said?